دورية أكاديمية
Clinical and pathologic factors predicting reclassification in active surveillance cohorts.
| العنوان: | Clinical and pathologic factors predicting reclassification in active surveillance cohorts. |
|---|---|
| المؤلفون: | Sierra PS; Fundacion Valle del Lili -Universidad Icesi, Cali, Colombia., Damodaran S; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Jarrard D; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.; University of Wisconsin Carbone Cancer Center, Madison, WI, USA. |
| المصدر: | International braz j urol : official journal of the Brazilian Society of Urology [Int Braz J Urol] 2018 Mar-Apr; Vol. 44 (3), pp. 440-451. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Brazilian Society of Urology Country of Publication: Brazil NLM ID: 101158091 Publication Model: Print Cited Medium: Internet ISSN: 1677-6119 (Electronic) Linking ISSN: 16775538 NLM ISO Abbreviation: Int Braz J Urol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Rio de Janerio, RJ, Brazil : Brazilian Society of Urology, [2002]- |
| مواضيع طبية MeSH: | Prostatic Neoplasms/*pathology , Risk Assessment/*methods , Watchful Waiting/*methods, Biopsy ; Disease Progression ; Humans ; Male ; Neoplasm Grading ; Nomograms ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/classification ; Prostatic Neoplasms/diagnosis ; Risk Factors ; Tumor Burden |
| مستخلص: | The incidence of small, lower risk well-differentiated prostate cancer is increasing and almost half of the patients with this diagnosis are candidates for initial conservative management in an attempt to avoid overtreatment and morbidity associated with surgery or radiation. A proportion of patients labeled as low risk, candidates for Active Surveillance (AS), harbor aggressive disease and would benefit from definitive treatment. The focus of this review is to identify clinicopathologic features that may help identify these less optimal AS candidates. A systematic Medline/PubMed Review was performed in January 2017 according to PRISMA guidelines; 83 articles were selected for full text review according to their relevance and after applying limits described. For patients meeting AS criteria including Gleason Score 6, several factors can assist in predicting those patients that are at higher risk for reclassification including higher PSA density, bilateral cancer, African American race, small prostate volume and low testosterone. Nomograms combining these features improve risk stratification. Clinical and pathologic features provide a significant amount of information for risk stratification (>70%) for patients considering active surveillance. Higher risk patient subgroups can benefit from further evaluation or consideration of treatment. Recommendations will continue to evolve as data from longer term AS cohorts matures. Competing Interests: Conflict of interest: None declared. (Copyright® by the International Brazilian Journal of Urology.) |
| References: | Urology. 2015 Jan;85(1):147-53. (PMID: 25440986) J Natl Cancer Inst. 1998 May 20;90(10):766-71. (PMID: 9605647) Prostate. 2015 Jun 15;75(9):947-56. (PMID: 25808608) Urology. 2016 Sep;95:139-44. (PMID: 27130265) Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90. (PMID: 23069729) J Clin Oncol. 2011 Jun 1;29(16):2185-90. (PMID: 21464416) J Urol. 2015 Sep;194(3):680-4. (PMID: 25636657) Ann Intern Med. 2013 Jun 18;158(12):853-60. (PMID: 23778902) BJU Int. 2009 Dec;104(11):1556-8. (PMID: 20053186) World J Urol. 2017 May;35(5):729-735. (PMID: 27631325) Rev Urol. 2016;18(3):123-132. (PMID: 27833462) J Urol. 2011 Mar;185(3):869-75. (PMID: 21239008) J Clin Oncol. 2016 Jun 20;34(18):2182-90. (PMID: 26884580) BJU Int. 2010 Nov;106(9):1309-14. (PMID: 20438566) JAMA. 1997 May 14;277(18):1445-51. (PMID: 9145716) BJU Int. 2017 May;119(5):692-699. (PMID: 27367469) Urology. 2015 Jan;85(1):155-60. (PMID: 25440814) J Urol. 2012 May;187(5):1594-9. (PMID: 22425088) Urology. 2009 May;73(5):1087-91. (PMID: 19195695) Eur Urol. 2015 Apr;67(4):646-8. (PMID: 25435266) Urol Oncol. 2015 May;33(5):201.e1-8. (PMID: 25791753) Jpn J Clin Oncol. 2013 May;43(5):553-8. (PMID: 23580758) J Urol. 2013 Jan;189(1):86-91. (PMID: 23158413) Eur Urol. 2015 Mar;67(3):569-76. (PMID: 25257029) Eur Radiol. 2012 Apr;22(4):746-57. (PMID: 22322308) J Urol. 2016 May;195(5):1409-1414. (PMID: 26707510) J Clin Oncol. 2005 Oct 20;23(30):7546-54. (PMID: 16234520) CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415) BJU Int. 2015 Feb;115(2):216-22. (PMID: 24904995) BJU Int. 2011 May;107(10):1582-6. (PMID: 20860650) Prostate Cancer Prostatic Dis. 2011 Mar;14(1):53-7. (PMID: 20938463) BJU Int. 2011 Oct;108(8 Pt 2):E171-8. (PMID: 21426475) J Clin Oncol. 2013 Apr 10;31(11):1428-34. (PMID: 23460710) Urol Oncol. 2015 Jul;33(7):329.e13-9. (PMID: 25960411) Prostate Cancer. 2013;2013:560857. (PMID: 23476788) J Natl Cancer Inst Monogr. 2012 Dec;2012(45):175-83. (PMID: 23271770) Asian J Androl. 2016 Jul-Aug;18(4):639-43. (PMID: 26732103) Eur Urol. 2014 Aug;66(2):337-42. (PMID: 24035632) Eur Urol. 2013 Dec;64(6):876-92. (PMID: 23787356) Prostate Cancer Prostatic Dis. 2017 Sep;20(3):339-342. (PMID: 28417979) Eur Urol. 2013 Apr;63(4):597-603. (PMID: 23159452) J Urol. 1995 Jul;154(1):131-8. (PMID: 7539857) J Urol. 2013 Dec;190(6):2039-45. (PMID: 23820059) BJU Int. 2013 Jan;111(1):53-9. (PMID: 22726582) Eur Urol. 2012 May;61(5):1019-24. (PMID: 22336380) JAMA. 2015 Jul 7;314(1):80-2. (PMID: 26151271) Eur Urol. 2015 Apr;67(4):637-45. (PMID: 25454617) World J Urol. 2012 Apr;30(2):143-8. (PMID: 22116601) Clin Cancer Res. 2013 May 1;19(9):2442-50. (PMID: 23515404) Prostate Cancer Prostatic Dis. 2015 Dec;18(4):382-7. (PMID: 26439747) Clin Cancer Res. 2015 Jun 1;21(11):2591-600. (PMID: 25733599) Int J Mol Sci. 2013 Jun 03;14(6):11816-29. (PMID: 23736690) Eur Urol. 2017 Apr;71(4):618-629. (PMID: 27568654) J Urol. 2011 Dec;186(6):2221-7. (PMID: 22014803) Eur Urol. 2016 Mar;69(3):428-35. (PMID: 26166626) Eur Urol. 2017 Oct;72(4):534-541. (PMID: 27816297) Eur Urol. 2013 Jan;63(1):101-7. (PMID: 22980443) Eur Urol. 2006 May;49(5):820-6. (PMID: 16439050) J Urol. 2011 Feb;185(2):471-6. (PMID: 21167525) J Urol. 2015 Aug;194(2):343-9. (PMID: 25681290) Cancer. 2013 Nov 15;119(22):3992-4002. (PMID: 24006289) J Urol. 2015 Sep;194(3):615-6. (PMID: 26079332) J Urol. 2006 Sep;176(3):979-84; discussion 984. (PMID: 16890675) J Urol. 2007 Jun;177(6):2106-31. (PMID: 17509297) Urology. 2015 Apr;85(4):742-7. (PMID: 25709045) Urol Oncol. 2013 Oct;31(7):1033-7. (PMID: 22206627) Eur Urol. 2015 Aug;68(2):194-5. (PMID: 25465969) Eur Urol. 2013 Oct;64(4):530-9. (PMID: 23759326) J Clin Oncol. 2006 Jul 20;24(21):3445-50. (PMID: 16849760) Eur Urol. 2014 Jul;66(1):30-1. (PMID: 24731786) J Clin Oncol. 2015 Jan 20;33(3):272-7. (PMID: 25512465) J Clin Oncol. 2011 Jul 10;29(20):2795-800. (PMID: 21632511) Eur Urol. 2015 Aug;68(2):186-93. (PMID: 25454609) Cancer. 2007 Jun 15;109(12):2432-8. (PMID: 17497649) J Clin Oncol. 2013 Aug 20;31(24):2991-7. (PMID: 23775960) J Urol. 2011 Nov;186(5):1830-4. (PMID: 21944136) |
| فهرسة مساهمة: | Keywords: Neoplasm Grading; Prostatic Neoplasms |
| المشرفين على المادة: | EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20180126 Date Completed: 20180719 Latest Revision: 20231112 |
| رمز التحديث: | 20231112 |
| مُعرف محوري في PubMed: | PMC5996796 |
| DOI: | 10.1590/S1677-5538.IBJU.2017.0320 |
| PMID: | 29368876 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1677-6119 |
|---|---|
| DOI: | 10.1590/S1677-5538.IBJU.2017.0320 |